NCT06044467已完成1 期
A Phase 1B, Repeated Dose Study, to Evaluate the Safety, PD and PK Profile of CM-101 in NAFLD Patients With Normal Liver Function Tests and Stable NAFLD/NASH Patients With NAFLD Activity Score (NAS) < 3-The SPARK Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Incidence and characteristics of adverse events (AEs) occurring following multiple doses
研究概览
简要总结
A two-part study for NAFLD subjects with normal liver functions and in general good health to be treated with CM-101 or matching placebo and NAFLD/NASH Activity Score (NAS) < 3 that are in general good health and have normal liver functions to be treated with CM-101.
详细描述
This study is designed to assess the safety and preliminary pharmacodynamics of repeated administrations of CM-101 in two subject populations. The objective of part one of this study is to demonstrate that repeated treatment with CM-101 will be safe and well tolerated in NAFLD subjects that have normal liver functions and are in general good health. A second expansion part will be carried out that will include patients with NAFLD/NASH Activity Score (NAS) < 3 that are in general good health and have normal liver functions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with US confirmation of NAFLD without evidence of NASH;
- •Patients with normal liver function tests (i.e. ALT, AST and ALP).
- •Patients in general good health expected for the preceding 6 months;
- •Women of childbearing potential must agree to use an approved form of contraception prior to study entry and for the duration of study participation through 60 days after the last dose of the study medication. Confirmation that female patients are not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for postmenopausal or surgically sterilized women;
- •Male patients must agree to use a barrier method of contraception or abstinence for the duration of study participation through 60 days after the last dose of the study medication;
- •Patient must be able to read, understand, and sign the informed consent forms (ICF), communicate with the investigator, and understand and comply with protocol requirements
排除标准
- •Patients with medical/surgical history of gastric bypass surgery, orthotopic liver transplant (OLT) or patients that are planned for such interventions;
- •Documented history of chronic liver disease (e.g., autoimmune hepatitis (>1:160 ANA with histologic features), Wilson's disease, Hemochromatosis (Ferritin >500 ug/L and percent iron saturation >45%), Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Alcoholic Liver Disease);
- •Presence of chronic viral hepatitis:
- •Chronic hepatitis B virus (HBV) infection (hepatitis B surface antigen (HBsAg) positive);
- •Chronic hepatitis C virus (HCV) infection (HCV Ab and HCV ribonucleic acid (HCV RNA) positive).
- •Patients cured of HCV infection less than 5 years prior to the Screening visit are not eligible;
- •History of or current diagnosis of HCC;
- •Known human immunodeficiency virus (HIV) infection (HIV Ab and HIV ribonucleic acid (HIV RNA) positive);
- •Patients with diabetes mellitus type 1;
- •Patients with uncontrolled diabetes mellitus type 2, i.e. HbA1c ≥ 9% (75 mmol/mol) at the time of screening or patients that are treated with insulin;
- •Patients treated with chronic medication including but not limited to anti-retrovirals, tamoxifen, methotrexate, cyclophosphamide, isotretinoin, bile acid binding resins, or pharmacologic doses of oral glucocorticoids (≥10 mg of prednisone per day or equivalent) within the 12 weeks of screening;
- •Patients treated with the below listed medications can be enrolled into the study if these medications are deemed medically necessary, cannot be stopped and the investigator anticipates their dose will remain stable during the study:
- •Stable doses of anti-diabetic medications (e.g. metformin, sulfonylureas, SGLT2 inhibitors, glitazones (thiazolidinediones), dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 analogs) for at least 6 months prior to screening.
- •Stable doses of ACE inhibitors, angiotensin II receptor antagonists, beta-blockers and thiazide diuretics for at least 6 months prior to screening.
- •Stable doses of fibrates, statins, niacin, ezetimibe for at least 6 months prior to screening.
- •Stable doses of vitamin E for at least 6 months prior to screening.
- •Replacement therapy (e.g., thyroxine, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is allowed as long as the treatment is stable forat least 6 months prior to screening. For further clarification Insulin treatment is not allowed.
- •Patients with the following medical conditions:
- •Cardiovascular conditions:
- •Unstable angina (clinical definition)
- •History of myocardial infarction, cardiac catheterization (for any reason) or coronary artery bypass graft within 18 months of screening
- •Atrial fibrillation
- •Congestive Heart failure (clinical definition) or hypertrophic cardiomyopathy
- •Heart valve disorder (i.e., prosthetic valve or known hemodynamically relevant valve disease)
- •Unstable angina
- •Uncontrolled thyroid disease
- •Portal hypertension
- •CNS disturbance such as history of Stroke (CVA and/or TIA), Parkinson's disease, Alzheimer's disease, or history of seizure disorders.
- •Autoimmune disease that has required systemic treatment in the 2 years preceding study screening (i.e., with the use of disease-modifying agents, corticosteroids or immunosuppressive drugs).
- •Clinically significant renal dysfunction defined as a serum creatinine concentration >1.4 mg/dL (females) or >1.6 mg/dL (males) and/or a blood urea nitrogen (BUN) concentration >45 mg/dL at screening.
- •Patients diagnosed or treated for any malignancy within 5 years of screening, except in situ malignancy, or low-risk prostate, skin (basal or squamous cell cancer or other localized non-melanoma) or cervix cancer after curative therapy.
- •Any laboratory abnormality or condition that, in the investigator's opinion, could adversely affect the safety of the patient or impair the assessment of study results.
- •Presence of any condition that could, in the opinion of the investigator, compromise the patient's ability to participate in the study, including a history of substance abuse or a psychiatric condition requiring hospitalization or emergency room visit within 2 years of Screening;
- •Patients with the following blood test abnormalities:
- •Abnormal coagulation tests: INR,
- •Total bilirubin (TB) ≥2 ULN,
- •Serum Albumin < 3.4 g/dL,
- •Platelet count <130 × 10^9/L;
- •History of or current significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening (significant alcohol consumption is defined as more than 20 g/day in females and more than 30 g/day in males, on average);
- •Patients with history of substance abuse (including alcohol abuse as defined above) in the past or a positive screen for drugs of abuse (opioids and cannabinoids) or alcohol at screening;
- •Female patients who are pregnant or nursing, or male/female patients who are planning a pregnancy during the course of the study;
- •Patients that are unavailable for follow-up assessments or any concern the investigator may have for patient's compliance with the protocol procedures;
- •Patients that are currently participating or have participated in an interventional clinical study within 3 months prior to screening
研究组 & 干预措施
Anti-human CCL24 monoclonal antibody (CM-101) - study Part One
Experimental
Anti-human CCL24 monoclonal antibody (CM-101)
NAFLD subjects that have normal liver functions - (Cohort 1: 2.5 mg/kg intravenously and Cohort 2: 5.0 mg/kg subcutaneously)
干预措施: Anti-human CCL24 monoclonal antibody (CM-101) - Part One (Drug)
Placebo - Study Part One
Placebo Comparator
Placebo Comparator
干预措施: Placebo - Study Part One (Drug)
Anti-human CCL24 monoclonal antibody (CM-101) - Study Part Two
Experimental
Anti-human CCL24 monoclonal antibody (CM-101)
NAFLD/NASH patients with NAS < 3 that are in general good health and have normal liver functions - 2.5 mg/kg intravenous infusion
干预措施: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two (Drug)
Placebo - Study Part Two
Placebo Comparator
Placebo Comparator
干预措施: Placebo - Study Part Two (Drug)
结局指标
主要结局
Incidence and characteristics of adverse events (AEs) occurring following multiple doses
时间窗: Up to 18 weeks
Incidence and characteristics of adverse events (AEs) occurring following multiple doses
Evaluation of the development of anti-drug antibodies (ADA) - Study Part 1
时间窗: Up to 18 weeks
Evaluation of the development of anti-drug antibodies (ADA) following repeated administrations of CM-101 -
次要结局
- Liver function test: ALT (alanine aminotransferase) - Study Part 2 Only(Over a treatment period of 18 weeks)
- Plasma Pharmacokinetics (PK) parameters of CM-101 following multiple administrations - Maximum CM-101 plasma concentration (Cmax) - Study Part 2(Up to 18 weeks)
- Plasma Pharmacokinetics (PK) parameters of CM-101 following multiple administrations - Time to Cmax (tmax) - Study Part 2(Up to 18 weeks)
- Liver function test: AST (Aspartate Aminotransferase) - Study Part 2 Only(Over a treatment period of 18 weeks)
- Liver function test: GGT (gamma-glutamyltransferase) - Study Part 2 Only(Over a treatment period of 18 weeks)
- Liver function test: ALP (Alkaline Phosphatase) - Study Part 2 Only(Over a treatment period of 18 weeks)
- Change from baseline to end of treatment in: Aspartate transaminase (AST) ratio - Study Part 2 Only(Up to 15 Weeks)
- Change from baseline to end of treatment in: Nonalcoholic fatty liver disease (NAFLD) Fibrosis Score - Study Part 2 Only(Up to 15 Weeks)
- Plasma Pharmacokinetics (PK) parameters of CM-101 following multiple administrations - Maximum CM-101 plasma concentration (Cmax) - Study Part 1(Up to 18 weeks)
- Plasma Pharmacokinetics (PK) parameters of CM-101 following multiple administrations - Terminal elimination half-life (T½) - Study Part 1(Up to 18 weeks)
- Plasma Pharmacokinetics (PK) parameters of CM-101 following multiple administrations - Area under the curve (AUC) to the final concentration ≥ limit of quantitation (LOQ), AUC(0-t) and to infinity AUCinf - Study Part 2(Up to 18 weeks)
- Plasma Pharmacokinetics (PK) parameters of CM-101 - Terminal elimination rate constant (λz) - Study Part 2(Up to 18 weeks)
- Plasma Pharmacokinetics (PK) parameters of CM-101 - Terminal elimination half-life (T½) - Study Part 2(Up to 18 weeks)
- Change from baseline to end of treatment in: Alanine aminotransferase (ALT) ratio - Study Part 2 Only(Up to 15 Weeks)
- Plasma Pharmacokinetics (PK) parameters of CM-101 - Time to Cmax (tmax) - Study Part 1(Up to 18 weeks)
- Plasma Pharmacokinetics (PK) parameters of CM-101 - Area under the curve (AUC) to the final concentration ≥ limit of quantitation (LOQ), AUC(0-t) and to infinity AUCinf - Study Part 1(Up to 18 weeks)
- Plasma Pharmacokinetics (PK) parameters of CM-101 following multiple administrations - Terminal elimination rate constant (λz) - Study Part 1(Up to 18 weeks)
- Evaluation of the development of anti-drug antibodies (ADA) following repeated administrations of CM-101 - Study Part 2(Up to 18 weeks)
- Change from baseline to end of treatment in: fibrosis-4 (FIB-4) score - Study Part 2 Only(Up to 15 Weeks)
- Change from baseline to end of treatment in: APRI (AST to platelet ratio index) - Study Part 2 Only(Up to 15 Weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
2-Week Study In People With Nonalcoholic Fatty Liver DiseaseNon-alcoholic Fatty Liver DiseaseNon-alcoholic SteatohepatitisNCT03513588Pfizer48
进行中（未招募）
不适用
Phase II study to evaluate hepatic function and clinical aspects in patients with severe hepatic cirrhosis treated with multiple cycle of stem cells mobilisation by G-CSF administration. - NDHepatic cirrhosis with severe liver dysfunctionMedDRA version: 6.1Level: PTClassification code 10019663EUCTR2007-001705-21-ITAZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
已完成
1 期
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver DiseaseNon-alcoholic Fatty Liver DiseaseFatty Liver, NonalcoholicNAFLDNonalcoholic SteatohepatitisNASHNonalcoholic Fatty Liver DiseaseNCT05560607AstraZeneca19
已完成
1 期
A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver ImpairmentHepatic ImpairmentNCT04225936Bristol-Myers Squibb40
已完成
1 期
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination TreatmentNon-Small Cell Lung Carcinoma (NSCLC)Colorectal Cancer (CRC)Other Solid TumorsNCT04256707Karyopharm Therapeutics Inc126